CA2210986A1 - Procede visant a ameliorer l'efficacite du criblage de cellules fusionnees - Google Patents

Procede visant a ameliorer l'efficacite du criblage de cellules fusionnees

Info

Publication number
CA2210986A1
CA2210986A1 CA002210986A CA2210986A CA2210986A1 CA 2210986 A1 CA2210986 A1 CA 2210986A1 CA 002210986 A CA002210986 A CA 002210986A CA 2210986 A CA2210986 A CA 2210986A CA 2210986 A1 CA2210986 A1 CA 2210986A1
Authority
CA
Canada
Prior art keywords
cells
fusion
cell line
yac
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002210986A
Other languages
English (en)
Inventor
Aya Jakobovits
Margaret C. Hardy
Larry Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Fremont Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2210986A1 publication Critical patent/CA2210986A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

On divulgue une méthode pour améliorer l'efficacité du criblage des cellules de fusion pour déceler la présence de gènes recherchés. La méthode consiste à doter le gène recherché d'un marqueur pour surmonter la sensibilité d'un partenaire de fusion cellulaire immortalisant à certaines conditions du milieu. La méthode est illustrée par l'inclusion d'un marqueur dans les gènes d'immunoglobuline présents dans les lymphocytes B.
CA002210986A 1995-01-20 1996-01-19 Procede visant a ameliorer l'efficacite du criblage de cellules fusionnees Abandoned CA2210986A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37627995A 1995-01-20 1995-01-20
US376,279 1995-01-20

Publications (1)

Publication Number Publication Date
CA2210986A1 true CA2210986A1 (fr) 1996-07-25

Family

ID=23484361

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002210986A Abandoned CA2210986A1 (fr) 1995-01-20 1996-01-19 Procede visant a ameliorer l'efficacite du criblage de cellules fusionnees

Country Status (6)

Country Link
EP (1) EP0804604A2 (fr)
JP (1) JPH10512449A (fr)
KR (1) KR19980701536A (fr)
AU (1) AU4906696A (fr)
CA (1) CA2210986A1 (fr)
WO (1) WO1996022380A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
ES2645698T3 (es) 2001-11-30 2017-12-07 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
JP2005529873A (ja) 2002-04-12 2005-10-06 メダレックス インコーポレイテッド Ｃｔｌａ−４抗体を使用した治療の方法
EP1954311A4 (fr) 2005-12-07 2009-12-23 Medarex Inc Régimes d'escalade de dose d'anticorps ctla-4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2637613B1 (fr) * 1987-06-19 1991-09-27 Transgene Sa Procede de preparation de lignees cellulaires stables pour la production de proteines determinees, a partir d'animaux transgeniques; lignees cellulaires tumorales et proteines obtenues
JP3008208B2 (ja) * 1990-06-01 2000-02-14 武田薬品工業株式会社 新規ハイブリドーマ，その製造法および生理活性物質の製造法
AU675661B2 (en) * 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies

Also Published As

Publication number Publication date
WO1996022380A2 (fr) 1996-07-25
WO1996022380A3 (fr) 1996-09-12
EP0804604A2 (fr) 1997-11-05
JPH10512449A (ja) 1998-12-02
AU4906696A (en) 1996-08-07
KR19980701536A (ko) 1998-05-15

Similar Documents

Publication Publication Date Title
ES2301158T3 (es) Produccion de anticuerpos xenogenicos.
US6114598A (en) Generation of xenogeneic antibodies
US6162963A (en) Generation of Xenogenetic antibodies
JP2022071051A (ja) Ａｄａｍ６マウス
CA2468565C (fr) Animaux transgeniques porteurs de genes a chaine legere iglamba d'immunoglobuline humaine
EP2305027B1 (fr) Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus.
DE69634851T2 (de) Immortalisierter Fusionspartner von Kaninchen
AU778780B2 (en) Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US20040250307A1 (en) Transgenic avian species for making human and chimeric antibodies
KR19990044300A (ko) 키메라 동물 및 그의 제작법
JPH06500233A (ja) 異種免疫グロブリンを作る方法及びトランスジェニックマウス
CA2210986A1 (fr) Procede visant a ameliorer l'efficacite du criblage de cellules fusionnees
CA2702329A1 (fr) Production d'anticorps xenogeniques

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20020121